OrbiMed’s MALLINCKRODT PUBLIC LIMITED COMPANY MNK Stock Holding History

OrbiMed’s Portfolio MNK Stock Details MNK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-200,000	Closed	-$8.96M	–	152
2017 Q2	$8.96M	Buy	+200,000	New	+$8.77M	0.09%	100

Other funds holding MNK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

OrbiMed's MNK Position: Q4 2017 in Review

OrbiMed sold out of MALLINCKRODT PUBLIC LIMITED COMPANY (MNK) in Q4 2017, closing a stake of 1,472,700 shares — an estimated $55M sold.

OrbiMed first reported a position in MNK in Q3 2014 and held it in 13 quarters. The position peaked at $100M in Q1 2015. 343 funds tracked by Wall St. Rank hold MNK as of Q4 2017.

OrbiMed reported no remaining MALLINCKRODT PUBLIC LIMITED COMPANY position as of Q4 2017 after selling out during the quarter.
OrbiMed sold 1,472,700 MALLINCKRODT PUBLIC LIMITED COMPANY shares in Q4 2017, an estimated $55M.
OrbiMed first reported a position in MALLINCKRODT PUBLIC LIMITED COMPANY in Q3 2014 and held it in 13 quarters.
OrbiMed's MALLINCKRODT PUBLIC LIMITED COMPANY position peaked at $100M in Q1 2015.
343 funds tracked by Wall St. Rank held MALLINCKRODT PUBLIC LIMITED COMPANY as of Q4 2017.

Based on OrbiMed's 13F filing for Q4 2017, filed 14 Feb 2018.